Dr Patrick McManamny regularly counsels clients in relation to filing and management of international patent portfolios, freedom-to-operate issues, patentability and due diligence. His clients include large multi-national clients, start-up companies and research institutes. Patrick has also served a brief period as in-house counsel, which provided valuable insight into the responsibilities of this role.
Patrick manages the patent portfolios of a number of Japanese companies and travels there regularly to visit both clients and his extensive network of associate firms. He also keeps a finger on the pulse in Japan's thriving biotechnology industry.
16 Sep 2017
At FB Rice, we recognise that diversity is a strength and that we are a better firm for having people with different ethnicity, sex, gender identity, sexual orientation and backgrounds.
06 Sep 2016
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.